コンテンツへスキップ
Merck

SML0335

Sigma-Aldrich

Remacemide hydrochloride

≥98% (HPLC)

別名:

2-Amino-N-(1-methyl-1,2-diphenylethyl)-acetamide hydrochloride, FPL 12924AA, PR 934-423A

ログイン組織・契約価格を表示する


About This Item

実験式(ヒル表記法):
C17H20N2O · HCl
CAS番号:
分子量:
304.81
MDL番号:
UNSPSCコード:
12352200
PubChem Substance ID:
NACRES:
NA.77

品質水準

アッセイ

≥98% (HPLC)

形状

powder

保管条件

desiccated

white to beige

溶解性

H2O: >10 mg/mL

保管温度

room temp

SMILES記法

Cl.CC(Cc1ccccc1)(NC(=O)CN)c2ccccc2

InChI

1S/C17H20N2O.ClH/c1-17(19-16(20)13-18,15-10-6-3-7-11-15)12-14-8-4-2-5-9-14;/h2-11H,12-13,18H2,1H3,(H,19,20);1H

InChI Key

HYQMIUSWZXGTCC-UHFFFAOYSA-N

生物化学的/生理学的作用

Remacemide HCl is a low affinity NMDA antagonist with anticonvulsant properties. Remacemide also been shown to block voltage-dependent sodium channels.
Remacemide possesses neuroprotective and anti-epileptic actions. It supports reducing the frequency of seizures. Remacemide is also known to be a potential therapeutic for Huntington′s disease.

特徴および利点

This compound is featured on the Glutamate Receptors (Ion Channel Family) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

ピクトグラム

CorrosionExclamation markEnvironment

シグナルワード

Danger

危険有害性情報

危険有害性の分類

Acute Tox. 4 Oral - Aquatic Acute 1 - Eye Dam. 1

保管分類コード

11 - Combustible Solids

WGK

WGK 3

引火点(°F)

Not applicable

引火点(℃)

Not applicable


試験成績書(COA)

製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Robert Małek et al.
Polish journal of pharmacology, 55(5), 691-698 (2004-01-06)
Epilepsy belongs to common diseases of the brain. It affects approximately 1% of the population. The aim of epilepsy therapy is to keep the patient free of seizures without interfering with normal brain function. Unfortunately, about 30% of all epilepsies
Gillian P Bates et al.
Current opinion in neurology, 16(4), 465-470 (2003-07-19)
Research conducted over the past 10 years has uncovered molecular mechanisms that are likely to be important in the early stages of Huntington's disease pathogenesis. This review summarizes the resources and strategies that are in place in order to exploit
M W Jones et al.
Seizure, 11(2), 104-113 (2002-04-12)
Remacemide hydrochloride is a low-affinity, non-competitive NMDA receptor channel blocker under investigation for the treatment of epilepsy. This double-blind, placebo-controlled, multicentre study assessed the safety and efficacy of adjunctive remacemide hydrochloride or placebo, in adult patients with refractory epilepsy who
Kinga K Borowicz et al.
Epilepsy & behavior : E&B, 11(1), 6-12 (2007-07-03)
Using the mouse maximal electroshock-induced seizure model, indicative of tonic-clonic seizures in humans, the present study was aimed at characterizing the interaction between remacemide and valproate, carbamazepine, phenytoin, and phenobarbital. Isobolographic analysis indicated additive interactions between remacemide and valproate, carbamazepine
E H Aylward et al.
Brain research bulletin, 62(2), 137-141 (2003-11-26)
Previous research has demonstrated that longitudinal change in caudate volume could be observed over a period of 3 years in subjects with Huntington's disease (HD). The current pilot study was designed to determine whether measurement of caudate change on magnetic

資料

We offers many products related to ion channel family glutamate receptors for your research needs.

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)